Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
Cancer J
; 22(3): 190-5, 2016.
Article
en En
| MEDLINE
| ID: mdl-27341597
Initial investigations of immune-checkpoint therapy targeting Programmed cell death protein 1/programed death ligand 1 in unselected colorectal cancer (CRC) has shown limited to no activity. However, a subset of CRC, characterized by mismatch deficiency or microsatellite instability high (MSI-high), has shown robust early signals of antitumor activity with PD1 targeting. It is now clear that MSI-high CRC represents a unique molecular and immunological tumor subset. Further study and understanding of the immunological microenvironment of these tumors will be critical to continued success with immune-based approaches in MSI-high CRC. This review discusses the current biological understanding of MSI-high CRC and outlines the current and ongoing clinical trials investigating immunotherapy.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Reparación de la Incompatibilidad de ADN
/
Inmunoterapia
Límite:
Humans
Idioma:
En
Revista:
Cancer J
Asunto de la revista:
NEOPLASIAS
Año:
2016
Tipo del documento:
Article
Pais de publicación:
Estados Unidos